AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week Low – Here’s What Happened

Posted by Trevor Kearing on Mar 19th, 2026

AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) hit a new 52-week low on Thursday . The stock traded as low as $12.61 and last traded at $12.9320, with a volume of 445557 shares changing hands. The stock had previously closed at $13.85.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. JPMorgan Chase & Co. initiated coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 price target on the stock. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a report on Tuesday, February 17th. Leerink Partners started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price on the stock. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $28.00 price target for the company. Finally, Zacks Research upgraded shares of AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, AgomAb Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Read Our Latest Research Report on AgomAb Therapeutics

AgomAb Therapeutics Stock Performance

About AgomAb Therapeutics

(Get Free Report)

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.